Orion Oyj (FRA:OFK)

Market Cap	9.46B +25.2%
Revenue (ttm)	1.89B +22.5%
Net Income	500.30M +51.7%
EPS	3.56 +51.5%
Shares Out	n/a
PE Ratio	18.91
Forward PE	18.07
Dividend	1.80 (2.69%)
Ex-Dividend Date	Oct 19, 2026

Volume	n/a
Average Volume	10
Open	66.90
Previous Close	66.85
Day's Range	66.90 - 66.90
52-Week Range	47.60 - 74.85
Beta	n/a
RSI	43.04
Earnings Date	Apr 23, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 4,029
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OFK

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.